Verve Therapeutics Inc (VERV) News

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new...

Form POS AM - Post-Effective amendments for registration statement

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form POSASR - Post-effective Amendment to an automatic shelf registration statement

Form 8-K - Current report

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second...

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class...

Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 31...

Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class...

Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones

Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities